Royalty Pharma Acquires PTC’s Royalty Interest in Risdiplam for $650M

 Royalty Pharma Acquires PTC’s Royalty Interest in Risdiplam for $650M

Shots:

  • PTC Therapeutics to receive $650M as upfront in cash in exchange for ~43% of the risdiplam royalties, up to a specified amount while PTC maintains the majority of the risdiplam royalty stream and retains all economics associated with up to ~$400M in remaining regulatory and commercial milestones
  • The collaboration enables PTC to further develop and expand its innovative rare disorder portfolio, including its validated splicing, Bio-e and gene therapy platform
  • Risdiplam is an investigational SMN2 splicing modifier for SMA, its NDA is under the US FDA’s Priority Review with anticipated PDUFA date as Aug 24, 2020. The company is planning to submit MAA to the EMA as well as filings in other international markets

Click here to read full press release/ article | Ref: PTC Therapeutics | Image: RTTNews

Related News: The US FDA Delays its Decision on Roche’s Risdiplam for the Treatment of Spinal Muscular Atrophy

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post